Combination Index (CI) values at Effective Dose (ED) 75 for refametinib (MEKi) combined with copanlisib (PI3Ki) or lapatinib (Lap) in a panel of HER2-positive breast cancer cell lines including parental cells (-P) and matched models of acquired trastuzumab (-RES) or lapatinib (-L) resistance. Here, ERBB2 is linked to breast cancer.